Your Messages Inbox
Most Viewed Abstracts
1. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 2. Omega-3 fatty acids for bipolar disorder 3. Is folic acid good for everyone 4. ACS Releases Guidelines for HPV Vaccination 5. Vitamin D - A review Free full text
Your Article Summary
See Latest ArticlesBenefits of Pharmacogenomics in Drug Development-Earlier Launch of Drugs and Less Adverse Events
The Journal of Medical Systems, 04/16/09
Ohashi W et al. - PGx enables earlier launch of a drug with less cost, representing benefit to pharmaceutical companies, patients and public as a whole. Currently, pharmaceutical companies are reluctant to introduce pharmacogenomics (PGx) in their practice, since cost–benefit of PGx is obscure and methodology to use PGx in drug development has not been fully established yet.
Related Articles
Pharmacogenomic perspectives on the management of mood disorders
Psychiatric Bulletin, 10/02/09
Relevance Score: 87%
Pharmacogenomic variations in treatment protocols for childhood acute lymphoblastic leukemia
Pediatric Blood & Cancer, 10/02/09
Relevance Score: 83%
Role of gut microbiota in Crohns disease
Expert Review of Gastroenterology & Hepatology, 10/13/09
Relevance Score: 80%
Lack of Correlation Between Thiazide-Induced Hyperglycemia and Hypokalemia: Subgroup Analysis of Results from the Pharmacogenomic Evaluation of Antihypertensive Responses Study
Pharmacotherapy, 10/07/09
Relevance Score: 80%
Pharmacogenomics: Personalizing Drug Therapy
American Journal of Nursing, 10/01/09
Relevance Score: 80%
Today in Economics of Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Perception of the economic value of primary care services: A willingness to pay study
Health Policy, 12/03/09
Medicare Spending for Previously Uninsured Adults
Annals of Internal Medicine, 12/03/09
Public reporting and pay-for-performance programs in perioperative medicine
Cleveland Clinic Journal of Medicine, 12/02/09
Sponsor
Article Search
Sponsor
Sponsor